Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ: ARQT · IEX Real-Time Price · USD
8.50
-0.96 (-10.11%)
Apr 19, 2024, 2:37 PM EDT - Market open
-10.11%
Market Cap 974.38M
Revenue (ttm) 59.61M
Net Income (ttm) -262.14M
Shares Out 114.97M
EPS (ttm) -3.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,929,859
Open 9.36
Previous Close 9.45
Day's Range 8.48 - 9.46
52-Week Range 1.76 - 15.21
Beta 1.14
Analysts Buy
Price Target 27.71 (+226.19%)
Earnings Date May 7, 2024

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2020
Employees 296
Stock Exchange NASDAQ
Ticker Symbol ARQT
Full Company Profile

Financial Performance

In 2023, ARQT's revenue was $59.61 million, an increase of 1517.09% compared to the previous year's $3.69 million. Losses were -$262.14 million, -15.83% less than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is $27.71, which is an increase of 226.19% from the latest price.

Price Target
$27.71
(226.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arcutis Appoints David Topper as Chief Financial Officer

WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatolog...

9 days ago - GlobeNewsWire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

13 days ago - GlobeNewsWire

VKTX, JANX and these biotech stocks are surging in 2024

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

17 days ago - Invezz

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.

22 days ago - GlobeNewsWire

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Industry veteran with over 25 years' experience will continue to advance the company culture and grow the capabilities of Arcutis' workforce WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -...

5 weeks ago - GlobeNewsWire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 1 39.4% of children tr...

5 weeks ago - GlobeNewsWire

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own disea...

5 weeks ago - GlobeNewsWire

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...

6 weeks ago - GlobeNewsWire

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages 2-5 with atopic dermatitis New patient-reported outcomes including prurit...

6 weeks ago - GlobeNewsWire

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

7 weeks ago - GlobeNewsWire

Arcutis Announces Pricing of $150 Million Public Offering

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in im...

7 weeks ago - GlobeNewsWire

Arcutis Announces Proposed Public Offering

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...

7 weeks ago - GlobeNewsWire

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.

7 weeks ago - GlobeNewsWire

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven...

7 weeks ago - GlobeNewsWire

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.

2 months ago - GlobeNewsWire

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

2 months ago - GlobeNewsWire

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Novel steroid-free topical foam effectively controls seborrheic dermatitis Once-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age...

2 months ago - GlobeNewsWire

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this week Effective, safe, and very well-tolerated steroid-free foam provides r...

3 months ago - GlobeNewsWire

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE ...

3 months ago - GlobeNewsWire

Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved measur...

3 months ago - GlobeNewsWire

FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

WESTLAKE VILLAGE, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-derma...

4 months ago - GlobeNewsWire

FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

WESTLAKE VILLAGE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovati...

5 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BTTXEVLOHSCSSINT
6 months ago - Benzinga

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 202...

6 months ago - GlobeNewsWire

Arcutis to Report Third Quarter 2023 Financial Results

Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business update.

6 months ago - GlobeNewsWire